Characterisation of TP 53 abnormalities in chronic lymphocytic leukaemia

Abnormalities of TP53 in chronic lymphocytic leukaemia (CLL) correlate with aggressive disease and transformation. We studied 115 patients with CLL including 90 untreated, 25 with heavily pretreated/refractory CLL using fluorescent in situ hybridisation (FISH) to detect allelic loss at chromosome 17p and flow cytometry (FC) to test p53 protein overexpression. A total of 17 cases were identified with TP53 deletion and/or protein expression. Both tests correlated in 10 of 17 patients; in six, one or the other abnormality was detected and in one case, with a deletion, flow cytometry failed. Material for direct DNA sequencing was available in 14 of 17 cases. Mutations were found in seven cases. Five of 14 patients with allelic loss and seven of 13 expressing p53 protein had a mutation. These were single-base substitutions and were located in exons 5, 7 or 8. Mutations were not found in 13 of 14 other cases without deletions by FISH or protein expression. The incidence of p53 abnormalities in this series was 15%, with a significant difference between untreated patients (7%) and the pretreated/refractory group (50%; Po0.01). Abnormal p53 was predicted for shorter survival, regardless of the method used. We confirm that p53 abnormalities are more common in refractory CLL and that mutations occur at the known hot spots. Testing for TP53 deletions by FISH and protein expression by FC is an effective and simple way of screening patients who are likely to have aggressive disease. DNA sequencing adds little to these methods in identifying the population at risk. The Hematology Journal (2004) 5, 47–54. doi:10.1038/sj.thj.6200325

[1]  Cathleen A. Towey.  Flow , 2000, My Wilderness.

[2]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[3]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.

[4]  D. Catovsky,et al.  p53 abnormalities in splenic lymphoma with villous lymphocytes. , 2001, Blood.

[5]  N. Barnabas,et al.  Significance of p53 mutations in patients with chronic lymphocytic leukemia , 2001, Cancer.

[6]  R. Tennant,et al.  Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. , 2001, Carcinogenesis.

[7]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[8]  D. Lane,et al.  Exploiting the p53 pathway for cancer diagnosis and therapy. , 1999, British journal of cancer.

[9]  E. Koníková,et al.  Flow cytometry of p53 protein expression in some hematological malignancies. , 1999, Neoplasma.

[10]  F. Mancini,et al.  p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. , 1998, Blood.

[11]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[12]  Patricia Rodriguez-Tomé,et al.  IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools , 1998, Nucleic Acids Res..

[13]  M. Dyer,et al.  p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis , 1997, British journal of haematology.

[14]  C. Preudhomme,et al.  THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIES , 1997, British journal of haematology.

[15]  J. Piette,et al.  Mdm2: keeping p53 under control , 1997, Oncogene.

[16]  H. Saito,et al.  Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[17]  G. Fleuren,et al.  Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. , 1997, Cytometry.

[18]  T. Crook,et al.  p53 abnormalities in B-cell prolymphocytic leukemia. , 1997, Blood.

[19]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[20]  D. Catovsky,et al.  Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients , 1996, British journal of haematology.

[21]  E. Newcomb.  P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. , 1995, Leukemia & lymphoma.

[22]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[23]  V. Rotter,et al.  Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. , 1994, Blood.

[24]  B. Quesnel,et al.  Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. , 1994, Leukemia.

[25]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[26]  G. Gaidano,et al.  Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. , 1994, The American journal of pathology.

[27]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[28]  K. Ishizaki,et al.  Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. , 1992, Cancer research.

[29]  C. Preudhomme,et al.  Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. , 1992, Leukemia.

[30]  E. Newcomb,et al.  p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. , 1992, Cancer research.

[31]  C. Midgley,et al.  p53 immunostaining as a marker of malignant disease in diagnostic cytopathology , 1991, The Lancet.

[32]  R. Metcalf,et al.  p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. , 1991, Cancer research.

[33]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[34]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[36]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .